DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Regenxbio's rolling BLA submission completion of RGX-121 for the treatment of patients with MPS II expected in Q1 of 2025.

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a ...

Dame Judi Dench has given an update on her failing eyesight due to macular disease, admitting that she can no longer leave ...

Age-related macular degeneration (AMD) affects more than 266 million people worldwide, and around 90% of these have the dry form of the disease. AMD is a multifactorial disorder with a genetic ...

Age-related macular degeneration may cause a gradual reduction in your central vision over time, so you might not recognize AMD at first.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in ...

The Amsler grid is a simple and effective tool often used to detect early signs of macular degeneration. This is a grid of ...

US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Pulsesight Therapeutics SAS has submitted a clinical trial authorization (CTA) to the French authority ANSM seeking to conduct a first-in-human phase I trial of PST-611 for dry age-related macular ...